VK-0214

Viking Therapeutics to present Phase 2 VENTURE study results of subcutaneous VK2735 in obese patients and Phase 1 trial results of oral VK2735 in healthy subjects at ObesityWeek® 2024. VK2735 is a GLP-1/GIP receptor dual agonist for metabolic disorders.

Leerink Partners analyst Thomas Smith reiterates Buy rating on VKTX stock, citing promising clinical trial results of VK-0214 for X-ALD and upcoming data from VK-2735 obesity program.

Viking Therapeutics reports positive Phase Ib trial results for VK0214, a thyroid hormone receptor beta agonist, in X-linked adrenoleukodystrophy patients. VK0214 showed safety, tolerability, and significant reductions in plasma very long-chain fatty acids and other lipids compared to placebo.

Viking Therapeutics Inc. (VKTX) released Phase 1b trial data of VK0214, a TRβ agonist for X-linked adrenoleukodystrophy (X-ALD), showing safety, tolerability, and significant reductions in very long-chain fatty acids (VLCFAs) and other lipids. VK0214 also reduced key diagnostic markers and plasma lipids, with mild to moderate adverse events. The trial's success expands Viking's potential revenue streams into the rare disease market.

Viking Therapeutics (VKTX) is advancing VK2735, an obesity treatment, to phase 3 trials, with an FDA meeting expected by year-end. The weight loss drug market is booming, with global sales reaching $24 billion in 2022, projected to hit $150 billion by the 2030s. Viking is also developing an oral form of VK2735 and other treatments for liver disease and a rare neurodegenerative condition. The stock is considered a strong buy.

DelveInsight's 'Adrenoleukodystrophy Pipeline Insight, 2024' report details 11+ treatment therapies by 10+ companies, including Autobahn Therapeutics, Viking Therapeutics, and SwanBio Therapeutics. Emerging therapies like ABX-002, VK0214, and SBT101 are expected to impact the market. Minoryx Therapeutics plans to re-examine Nezglyal's approval after CHMP's refusal.

Viking Therapeutics announced positive Phase 2 trial results for VK2735, showing significant weight loss up to 14.7% from baseline and 13.1% over placebo after 13 weeks. The treatment was safe, well-tolerated, with most adverse events being mild or moderate. Viking plans to discuss next steps with the FDA.